Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study) |
| |
Authors: | Rogério A Costa Rodrigo Jorge Daniela Calucci Jr" target="_blank">Luiz A S MeloJr José A Cardillo Ingrid U Scott |
| |
Institution: | 1.U.D.A.T. Macular Imaging & Treatment Division,Hospital de Olhos de Araraquara,Araraquara,Brazil;2.Retina and Vitreous Section, Department of Ophthalmology, School of Medicine of Ribeir?o Preto,University of S?o Paulo,Ribeir?o Preto,Brazil;3.Departments of Ophthalmology and Health Evaluation Sciences,Penn State College of Medicine,Hershey,USA |
| |
Abstract: | Background A novel alternative for combined treatment using verteporfin photodynamic therapy (PDT) has emerged as preliminary safety
and efficacy data of the intravitreal use of the anti-angiogenic bevacizumab became available. In the current study we investigate
the feasibility of intravitreal bevacizumab combined with verteporfin PDT for the treatment of choroidal neovascularization
(CNV) secondary to age-related macular degeneration (AMD).
Methods A single-centre, prospective, open-label study of 11 patients with documented CNV progression after PDT treatment who underwent
combined PDT and intravitreal injection of 1.5 mg of bevacizumab was undertaken. Standardized ophthalmic evaluation was performed
at baseline and at weeks 1, 2, 12 and 24. Clinical evidence of complications and changes in logarithm of the minimum angle
of resolution (logMAR) best-corrected visual acuity (BCVA) using Early Treatment Diabetic Retinopathy Study (ETDRS) charts
and in fluorescein leakage from CNV were evaluated.
Results The mean (±SD) age of the 11 patients was 74 (±5) years. Seven eyes had been treated with one previous PDT session and four
eyes had two previous PDT sessions. The mean baseline logMAR ETDRS BCVA was 1.031 (Snellen equivalent, 20/200−2). At follow-up weeks 1, 2, 12 and 24, the mean logMAR ETDRS BCVA (Snellen equivalent) was 0.944 (20/160−2), 0.924 (20/160−1), 0.882 (20/160+1), and 0.933 (20/160−2), respectively. The change in BCVA from baseline was significant at each study follow-up interval (P ≤ 0.001); at 12 and 24 weeks, the mean change in BCVA from baseline was an improvement of 1.49 and of 0.98 ETDRS line, respectively.
Fluorescein leakage from CNV was absent in all eyes at week 12. One additional treatment session was required in seven (63.6%)
eyes at week 24 due to recurrent fluorescein leakage from CNV (“minimum” <50% of the leaking area noted at baseline], n = 4; and “moderate” >50% of the leaking area noted at baseline], n = 3). No progression of the neovascular lesion was observed at week 24. No safety issues were identified throughout the period
of the study.
Conclusions The overall changes in vision and fluorescein leakage from CNV throughout the study suggest that a possible synergistic effect
may arise from the combination of intravitreal bevacizumab with verteporfin PDT for the treatment of neovascular AMD.
In terms of funding, this was an investigator’s driven study. |
| |
Keywords: | Angiogenesis Laser Neovascularization Choroid Pegaptanib Ranibizumab Vascular endotelhial growth factor (VEGF) |
本文献已被 SpringerLink 等数据库收录! |
|